TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Similar to the therapeutic effect of CD20 monoclonal antibodies in B-cell lymphomas, there is an increasing interest in targeting CD30 as a potential therapeutic option for PTCL [102].